About this trial
Orofacial clefts are among the most common congenital malformations, affecting approximately 1 in 700-1500 live births worldwide. They are associated not only with aesthetic concerns but also with functional impairments in feeding, speech, hearing, and dentition, and may be accompanied by other systemic malformations, often requiring multiple surgical procedures and long-term multidisciplinary care. Although cognitive development is preserved, the psychosocial impact on both children and families can be significant.
Anesthesia in children with clefts presents specific challenges. Airway management is often more difficult due to anatomical variations, particularly in syndromic patients and those under 1 year of age. Immature organ systems affect drug metabolism, requiring careful dose adjustment. Preoperative anxiety and stress responses are common and may contribute to complications such as laryngospasm and bronchospasm. In the postoperative period, emergence agitation (EA) and emergence delirium (ED) are frequent, with reported incidence up to 80%. These conditions are characterized by restlessness, inconsolability, and disorientation, and may result in self-injury or disruption of surgical repairs.
Differentiating agitation from pain is challenging in young children due to limited communication abilities. Validated observational tools such as CHIPPS, PAEDS, and Cravero scales are used for routine clinical assessment of pain and EA/ED, although their subjective nature may limit accuracy. Therefore, evaluation of the perioperative serum cortisol, alpha-amylase, and neuropeptide Y levels will be used. These biomarkers reflect activation of the physiological stress response and indirectly indicate the presence and intensity of pain.
Pain management requires a multimodal approach. While opioids remain standard, their use is associated with adverse effects such as respiratory depression, nausea, vomiting, and delayed recovery. Consequently, opioid-free (OF) strategies using different anesthetics, including ketamine and dexmedetomidine have gained attention.
This prospective randomized clinical trial will compare opioid-based anesthesia with an opioid-free protocol in children undergoing cleft surgery. A total of 90 patients age of 3 months-7 years will be randomized in a 1:1 ratio. The opioid group will receive fentanyl, while the OF group will receive ketamine and dexmedetomidine; both groups will receive propofol, vecuronium, sevoflurane, and nitrous oxide.
Primary outcomes are postoperative pain (CHIPPS) and emergence agitation (PAEDS, Cravero). Pain will be assessed at 5 min, 15 min, 1, 2, 12, and 24 h after extubation, whereas emergence agitation will be evaluated at 5 min, 15 min, 1 h, and 2 h post-extubation. While these scales are routinely used in clinical practice, their subjective nature necessitates additional objective assessment. Therefore, secondary outcomes include evaluation of perioperative stress markers (cortisol, alpha-amylase, neuropeptide Y) and adverse events (nausea, vomiting, pruritus, constipation, respiratory depression, altered consciousness) within 24 h. Procedures will be standardized, with morning surgeries to minimize circadian variations of the biomarkers, performed by the same team. Blood samples will be collected before and after intravenous induction.
Postoperative analgesia will include paracetamol and NSAIDs, with fentanyl as rescue therapy.
The study hypothesis is that opioid-free anesthesia will provide comparable or superior analgesia, reduce the incidence of emergence agitation, attenuate the stress response, and decrease opioid-related adverse effects, thereby improving overall perioperative safety and recovery in pediatric patients undergoing cleft surgery.
The particular value of this study lies in the subgroup of children who will undergo at least two surgical procedures within the observation period. In these patients, each child will be exposed to both anesthetic protocols in separate procedures-once according to the randomly assigned regimen and the second time according to the alternative protocol. In this way, each patient serves as their own control, allowing for a more precise comparison of outcomes with a substantial reduction in inter-individual variability. This approach largely eliminates individual differences such as age, body weight, baseline hemodynamic status, individual sensitivity to anesthetics and analgesics, as well as variability in stress response and pain perception. Such a design enhances the internal validity of the study and enables a more reliable interpretation of the results.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
ASA physical status I-II
Body weight >5 kg
Age ≥3 months for cleft lip repair and ≥9 months for cleft palate repair
Hemoglobin >100 g/L
Disqualifiers
ASA physical status III-IV
Body weight <5 kg
Age <3 months for cleft lip repair or <9 months for cleft palate repair
Hemoglobin <100 g/L
Trial design
Parallel
Treatments tested in this trial
Ketamine (1 mg/kg)
DrugKetamine administered as part of an opioid-free anesthesia protocol during pediatric cleft surgery.
Dexmedetomidine (1-0,8-0,6-0,4 mcg/kg/h)
DrugDexmedetomidine administered as part of an opioid-free anesthesia protocol during pediatric cleft surgery.
Fentanyl 5 mcg/kg
DrugFentanyl administered as part of an opioid-based anesthesia protocol during pediatric cleft surgery.
Propofol (IV) 3-4 mg/kg
DrugPropofol used for induction and/or maintenance of general anesthesia.
Sevoflurane (Volatile Anesthetic)
DrugSevoflurane used for maintenance of general anesthesia
Nitrous Oxide/Oxygen
DrugNitrous oxide used as an adjunct to general anesthesia.
Vecuronium (0.1 mg/kg)
DrugNeuromuscular blocking agent used to facilitate tracheal intubation and surgical conditions.
Treatment groups
Trial outcomes
Primary outcomes
Postoperative pain intensity assessed by the Children and Infants Postoperative Pain Scale (CHIPPS)
Postoperative pain will be assessed using the Children and Infants Postoperative Pain Scale (CHIPPS), a validated observational tool for pain assessment in infants and young children. Scores range from 0 to 10, with higher scores indicating more severe pain. Pain assessments will be performed at predefined time points: 5 minutes ,15 minutes, 30 minutes, 1 hour, 2 hours, 6 hours, 12 hours, and 24 hours after extubation. A CHIPPS score ≥4 is considered indicative of insufficient analgesia.
Emergence agitation assessed by the Pediatric Anesthesia Emergence Delirium Scale (PAEDS)
Emergence agitation will be assessed using the Pediatric Anesthesia Emergence Delirium Scale (PAEDS), a validated observational tool based on behavioral observation and consisting of five items: eye contact, purposeful actions, awareness of surroundings, restlessness, and inconsolability. Each item is scored from 0 to 4, with total scores ranging from 0 to 20. Higher scores indicate severe emergence delirium. Values ≥10 are commonly considered clinically significant.
Emergence agitation assessed by the Cravero Agitation Scale
Emergence agitation will also be assessed using the Cravero scale, an observational scale used for evaluation of postoperative agitation in pediatric patients. Agitation will be recorded at extubation and during the early postoperative recovery period at predefined intervals of 5 minutes ,15 minutes, 30 minutes, 1 hour and 2 hours after extubation. Higher scores indicate more pronounced agitation.
Secondary outcomes
Perioperative stress response assessed by serum cortisol levels
Serum cortisol levels will be measured at predefined perioperative time points to assess the physiological stress response associated with surgery and anesthesia.
Perioperative stress response assessed by serum alpha-amylase levels
Alpha-amylase levels will be measured as a biomarker of perioperative stress response. Samples will be collected at predefined time points, including before intravenous anesthesia induction and before emergence from anesthesia. Changes in alpha-amylase levels will be analyzed to compare the physiological stress response between opioid-free and opioid-based anesthesia protocols.
Perioperative stress response assessed by serum neuropeptide Y levels
Neuropeptide Y levels will be measured as a biomarker of perioperative stress response. Blood samples will be collected at predefined time points, including before intravenous anesthesia induction and before emergence from anesthesia. Changes in neuropeptide Y levels will be analyzed to assess the effect of opioid-free versus opioid-based anesthesia on the stress response.
Incidence of postoperative adverse events
The incidence of postoperative adverse events will be recorded and compared between the study groups. Adverse events will include respiratory complications (e.g., desaturation, airway obstruction), cardiovascular instability (e.g., bradycardia, hypotension), postoperative nausea and vomiting, excessive sedation, and other clinically relevant complications. Events will be monitored from anesthesia induction through the first 24 hours after surgery.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Iva Smiljanić
Lead sponsor
University of Zagreb
Sponsor institution
University of Zagreb
Collaborator
University Hospital Dubrava
Collaborator